

KELLERHALS CARRARD ADVISES ON CAPITAL INCREASE AND LISTING OF NEW SHARES OF YPSOMED

Posted on 29 June 2022



Category: [Capital Markets](#)

Tags: [Beat Brechbühl](#), [frederic rochat](#), [jörg von Manger-König](#), [Kellerhals Carrard](#), [Luca Bianchi](#), [reto schumacher](#), [Robin Juchler](#), [sx3](#), [ypsomed](#)



Kellerhals Carrard has advised **Ypsomed Holding** on CHF 122.5 million capital increase and listing of 1'000'000 new shares on SIX Swiss Exchange. The new registered shares were successfully listed. Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. Zürcher Kantonalbank acted as Sole Global Coordinator of this capital increase. The first trading day of the new registered shares was 28 June 2022.

[Kellerhals Carrard](#) advised Ypsomed and Zürcher Kantonalbank as Counsel to the Transaction on the capital increase and listing. The team was led by partner **Beat Brechbühl** (capital markets, pictured left), **Frédéric Rochat** (partner, capital markets, pictured right), **Luca Bianchi** (partner, capital markets), **Reto Schumacher** (partner, corporate), **Jörg von Manger-König** (Of Counsel, life sciences), **Philippe Frésard** (partner, notary), **Robin Juchler** (associate, capital markets) and **Christian Witschi** (partner, tax).